Soriot should explain the curious case of AstraZeneca’s non-deal
Steady4 outlets reported this in 4 reports over 2 days
Wed, 5 August 2026peak 2 reports on Wed, 5 August 2026Sun, 9 August 2026
What it is about
Bristol Myers SquibbPascal SoriotAstrazenecaReutersUnited KingdomBritainAstraZenecaBMSBolsa de Reino UnidoBristol Myers
Who published it, and when
original reportfirst to report
bioxconomy.com
theguardian.com
El País (Spain)
Libération (France)
5 Aug, 16:19over 4 days9 Aug, 04:57
How it spread - 4 original reports
Wed, 5 August 2026
2 reports- bioxconomy.com16:19first to report
Reuters has reported that an insider has shut down speculation surrounding a merger between AstraZeneca and Bristol Myers Squibb.
- theguardian.com17:45
AstraZeneca’s rumoured takeover of Bristol Myers Squibb already looked weird, and was met with a lack of enthusiasm by shareholders
Sun, 9 August 2026
2 reports- El País (Spain)03:40
El director ejecutivo de la segunda empresa con mayor valoración en Bolsa de Reino Unido vuelve a la palestra por una ya desmentida posible fusión con BMS
- Libération (France)04:57
Le labo britannique AstraZeneca aurait étudié l’acquisition de son concurrent américain Bristol Myers Squibb. Dictée par la quête de brevets, cette méga-fusion à 400 milliards de dollars relancerait la course à la taille dans l’industrie du médicament. Mais l’opération ne plaît pas aux marchés.